This clinical trial is focused on studying treatments for Acute Lymphoblastic Leukemia (ALL), a type of cancer that affects the blood and bone marrow. The study aims to improve the survival and quality of life for children and young adults diagnosed with this disease. Participants in the trial will receive various treatments, including medications like Tioguanine, Hydrocortisone Sodium Succinate, Mercaptopurine, Blinatumomab, Vincristine Sulfate, Doxorubicin, Dexamethasone, Methotrexate, Imatinib, Inotuzumab Ozogamicin, Methylprednisolone Sodium Succinate, Prednisolone Sodium Succinate, and Cytarabine. Some participants may receive a placebo as part of the study.

The purpose of the study is to test these treatments in a structured way to see how well they work and to gather information about their effects. The study will involve different phases where participants will receive these treatments over a period of time. The treatments will be given in various forms, such as oral suspensions, tablets, or injections, depending on the specific medication. The study will also explore the potential benefits of new types of treatments, such as immunotherapy, for certain groups of patients.

Throughout the study, participants will be monitored to assess the effectiveness of the treatments and to identify any side effects. The study will collect data on survival rates, the occurrence of any relapses, and the overall quality of life of the participants. This information will help researchers understand how these treatments can be used to improve outcomes for people with Acute Lymphoblastic Leukemia.